In a retrospective review, researchers assessed the effect of galcanezumab exposure during pregnancy on maternal and fetal outcomes and compared these outcomes to those seen with placebo.

In a single-center, randomized, staggered-start, open-label clinical trial, researchers evaluated rimegepant for short-term prevention of fasting-related headache in adults fasting during Ramadan.

In a network meta-analysis of data from the CHALLENGE-MIG trial, researchers evaluated the relative efficacy and safety of atogepant compared with rimegepant and galcanezumab for the preventive treatment of episodic migraine.

In a small retrospective review, researchers assessed safety and efficacy of CGRP-targeted vs propranolol/metoprolol therapies in patients with both dysautonomia and headache disorders.

In a post hoc analysis, researchers examined the association between atogepant use and weight loss in patients with overweight or obesity receiving treatment for episodic or chronic migraine.

Using data from the ASCEND trial, researchers determined the effect of STS101 on cardinal symptoms of migraine.

In a post hoc REVIEW study analysis, researchers compared self-reported outcomes by level of improvement in good days/month with eptinezumab.

In the phase 3 EMERGE trial, researchers evaluated the efficacy and safety of meloxicam and rizatriptan in patients with migraine undergoing treatment with gepant for less than a month and experiencing an inadequate response.

In a post hoc subgroup analysis of a phase 3 randomized, double-blind, sham-controlled clinical trial, researchers examined whether patients with migraine with vs without aura respond differently to a 2-hour eTNS treatment, using data from the TEAM study.

In a retrospective chart review, researchers assessed the prevalence of normal vs abnormal brain MRI findings in pediatric patients diagnosed with migraine.